Brought to you by 
Rempex Pharmaceuticals announces $67.5mm Series B
10 Nov 2011
Executive Summary
Start-up Rempex Pharmaceuticals Inc. (developing therapeutics aimed at antibiotic resistance) completed the first closing of a Series B financing that could reach $67.5mm. Participating in the round were new investors Frazier Healthcare Ventures and Vivo Ventures, along with returning shareholders SV Life Sciences, OrbiMed Advisors, and Adams Street Partners.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rempex Pharmaceuticals announces $67.5mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice